MX2021009637A - Tratamientos combinados para su uso en el tratamiento del cancer. - Google Patents

Tratamientos combinados para su uso en el tratamiento del cancer.

Info

Publication number
MX2021009637A
MX2021009637A MX2021009637A MX2021009637A MX2021009637A MX 2021009637 A MX2021009637 A MX 2021009637A MX 2021009637 A MX2021009637 A MX 2021009637A MX 2021009637 A MX2021009637 A MX 2021009637A MX 2021009637 A MX2021009637 A MX 2021009637A
Authority
MX
Mexico
Prior art keywords
mtap
deficient
treating cancer
combination therapies
treatment
Prior art date
Application number
MX2021009637A
Other languages
English (en)
Inventor
Katya Marjon
Marc Lee Hyer
Petar Kalev
Kevin Marks
Original Assignee
Les Laboratoires Servier Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier Sas filed Critical Les Laboratoires Servier Sas
Publication of MX2021009637A publication Critical patent/MX2021009637A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

El compuesto de Fórmula (I), o sus sales farmacéuticamente aceptables, es útil, entre otras cosas, en el tratamiento del cáncer de pulmón con deficiencia de MTAP, tal como NSCLC, o cáncer de páncreas con deficiencia de MTAP, tal como PDAC, o cáncer de esófago con deficiencia de MTAP y proporciona una ventaja terapéutica cuando se usa en combinación con otros agentes como se describe en la presente en comparación con el tratamiento con cada agente cuando se administra solo.
MX2021009637A 2019-02-13 2020-02-13 Tratamientos combinados para su uso en el tratamiento del cancer. MX2021009637A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962805179P 2019-02-13 2019-02-13
PCT/US2020/018036 WO2020168032A1 (en) 2019-02-13 2020-02-13 Combination therapies for use in treating cancer

Publications (1)

Publication Number Publication Date
MX2021009637A true MX2021009637A (es) 2021-10-01

Family

ID=70009364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009637A MX2021009637A (es) 2019-02-13 2020-02-13 Tratamientos combinados para su uso en el tratamiento del cancer.

Country Status (17)

Country Link
US (1) US20220133727A1 (es)
EP (1) EP3923950A1 (es)
JP (1) JP2022520802A (es)
KR (1) KR20220051302A (es)
CN (1) CN113453687A (es)
AU (1) AU2020221384A1 (es)
BR (1) BR112021015878A2 (es)
CA (1) CA3129832A1 (es)
CL (1) CL2021002146A1 (es)
CO (1) CO2021011319A2 (es)
EA (1) EA202192234A1 (es)
IL (1) IL285538A (es)
JO (1) JOP20210221A1 (es)
MX (1) MX2021009637A (es)
SG (1) SG11202108745RA (es)
TW (1) TW202045155A (es)
WO (1) WO2020168032A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023196545A1 (en) * 2022-04-08 2023-10-12 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
WO2006023010A1 (en) * 2004-08-18 2006-03-02 Salmedix, Inc. Alanosine formulations and methods of use
AU2017319500C1 (en) * 2016-08-31 2022-10-20 Les Laboratoires Servier Inhibitors of cellular metabolic processes
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes

Also Published As

Publication number Publication date
WO2020168032A1 (en) 2020-08-20
CA3129832A1 (en) 2020-08-20
JP2022520802A (ja) 2022-04-01
AU2020221384A1 (en) 2021-09-02
JOP20210221A1 (ar) 2023-01-30
CN113453687A (zh) 2021-09-28
CL2021002146A1 (es) 2022-03-11
US20220133727A1 (en) 2022-05-05
CO2021011319A2 (es) 2021-09-09
KR20220051302A (ko) 2022-04-26
IL285538A (en) 2021-09-30
EA202192234A1 (ru) 2021-11-03
SG11202108745RA (en) 2021-09-29
TW202045155A (zh) 2020-12-16
BR112021015878A2 (pt) 2021-10-05
EP3923950A1 (en) 2021-12-22

Similar Documents

Publication Publication Date Title
MX2021002886A (es) Terapia de combinacion para el tratamiento de cancer de mama triple negativo.
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
MX2022005994A (es) Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras.
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
HK1140141A1 (en) Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
BR112018070017A2 (pt) métodos de tratamento de cânceres pediátricos
TW201613589A (en) Combination methods for treating cancers
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
WO2018102687A3 (en) Combination therapy for treating cancer
MX2009006574A (es) Tratamiento de cancer de pulmon.
EA202190749A1 (ru) Способы комбинированной терапии
PH12021550713A1 (en) Medicament for the treatment of chronic cough
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
WO2015035410A8 (en) Cancer therapy
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
JOP20210221A1 (ar) علاجات مشتركة لاستخدامها في علاج السرطان
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом